Protein-bound paclitaxel

Society and culture

Abraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs. Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.

In 2010, Abraxis was acquired by Celgene, which now markets Abraxane. Total revenue from the sales of Abraxane for 2009 were $314.5 million. In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer. In 2014, Abraxane's sales were $848 million, 31 percent year-over-year increase. In 2019 Bristol Meyers Squibb acquired Celgene for $74 billion dollars, and thus acquired Abraxis Bioscience and the rights to manufacture and market Abraxane.

The UK's National Institute for Health and Care Excellence (NICE) announced in 2015, that it would not support the routine use of protein-bound paclitaxel in advanced pancreatic cancer on the NHS. However, this decision was changed in September 2017. It has continued to be reimbursed in England since then, despite questionable real world effectiveness.

References

References

1. (7 July 2016). "Product monograph brand safety updates".
2. (2011-02-02). "Definition of "protein-bound paclitaxel"". [[National Cancer Institute]] Dictionary of Cancer Terms.
3. "Nab-paclitaxel (Abraxane)".
4. (2006). "Paclitaxel Albumin-stabilized Nanoparticle Formulation". [[National Cancer Institute]] Drug Information.
5. (September 6, 2013). "Abraxane".
6. (August 27, 2020). "The Inside Story Of Biotech's Barnum And His Covid Cures".
7. (2006). "FDA Approval for Nanoparticle Paclitaxel". [[National Cancer Institute]] Drug Information.
8. (9 March 2020). "Abraxane EPAR".
9. (2012-10-12). "FDA approves Celgene's Abraxane for lung cancer". Reuters.
10. (October 11, 2012). "Paclitaxel (Abraxane)". U.S. [[Food and Drug Administration]].
11. (September 7, 2013). "F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer". [[New York Times]].
12. (June 6, 2008). "Resolution 9190". Therapeutic Goods Administration (Tga).
13. (May 2009). "Assessing the safety and cost-effectiveness of early nanodrugs". Journal of Law and Medicine.
14. (November 2008). "PBAC, Public Summary Document".
15. "Celgene: A Global Biopharmaceutical Company Committed to Improving the Lives of Patients Worldwide with Innovative and Life-Changing Treatments".
16. "Celgene Completes Acquisition of Abraxis".
17. (2010). "Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC".
18. "FDA approves Abraxane for late-stage pancreatic cancer".
19. "Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results (NASDAQ:CELG)".
20. Kansteiner, Fraiser. (2022-11-09). "Bristol Myers' subsidiary behind cancer blockbuster Abraxane slapped with FDA warning letter".
21. (September 2015). "NHS England stop access to Abraxane - Pancreatic Cancer UK".
22. (2017-09-06). "Overview {{!}} Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer {{!}} Guidance {{!}} NICE".
23. (August 2022). "Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England". Clinical Oncology.